463 patents
Page 8 of 24
Utility
Methods of Quantifying N2-(1-CARBOXYETHYL)-2'-DEOXY-GUANOSINE (Cedg) and Synthesis of Oligonucleotides Containing Cedg
20 Oct 22
Methods of quantifying a N2-(1-carboxyethyl)-2′-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer.
Samuel RAHBAR, Timothy W. SYNOLD, John TERMINI, Gerald WUENSCHELL, Daniel TAMAE, Sarah SHUCK
Filed: 22 Nov 21
Utility
Adeno-associated Virus Compositions for Restoring F8 Gene Function and Methods of Use Thereof
20 Oct 22
Provided herein are adeno-associated virus (AAV) compositions that can restore F8 gene function in cell.
Saswati CHATTERJEE, Laura Jane SMITH, Jeff Lynn ELLSWORTH, Hillard RUBIN, Jason Boke WRIGHT, James Anthony MCSWIGGEN
Filed: 10 Mar 22
Utility
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
11 Oct 22
The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
Filed: 24 Jul 20
Utility
Chimeric antigen receptors targeted to PSCA
11 Oct 22
Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.
Saul J. Priceman, Christine E. Brown, Stephen J. Forman
Filed: 6 Oct 16
Utility
Txnip-trx Complex Inhibitors and Methods of Using the Same
6 Oct 22
Disclosed herein, inter alia, are compounds and methods for inhibiting the thioredoxin-thioredoxin-interacting-protein (TXNIP-TRX) complex.
Rama Natarajan, Feng Miao, Nagarajan Vaidehi, Supriyo Bhattacharya, Adrien Beau Larsen
Filed: 6 Apr 22
Utility
Redirecting Death-inducing Signal Complex (Disc) by Modifying Death Receptor Agonist to Induce Cell Death for Cancer Treatment
29 Sep 22
It was found that TRAIL-induced death signaling was largely diminished by lysosomal degradation system.
Edward Wenge WANG
Filed: 24 Mar 22
Utility
IL1RAP Antibodies
29 Sep 22
Provided herein are, inter alia, Interleukin-1 receptor accessory protein (IL1RAP) antibodies and fragments thereof which may form part of chimeric antigen receptors or bispsecific antibodies and are useful for treating IL1RAP-expressing cancers.
Bin Zhang, Weixu Meng, Guido Marcucci
Filed: 12 Aug 20
Utility
Sumo Inhibitor Compounds and Uses Thereof
22 Sep 22
There are disclosed, inter alia, methods of inhibiting an E1 enzyme, and compounds useful for inhibiting an E1 enzyme.
Yuan CHEN, Xiaohu OUYANG, Sung Wook YI, Ted Charles JUDD
Filed: 31 Jul 19
Utility
Dual Bispecific Antibody Compounds and Uses Thereof
8 Sep 22
Provided herein, inter alia, are methods of using bispecific antibody compounds which may bind immune cells and are, inter alia, useful for treating cancers.
John E. SHIVELY, Maciej KUJAWSKI, Lin LI, Paul J. YAZAKI
Filed: 13 Aug 20
Utility
Margin extension device and method
6 Sep 22
A margin extension device and method are disclosed herein.
Gagandeep Singh, Jonathan Kessler
Filed: 5 Aug 19
Utility
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
6 Sep 22
Adeno-associated virus (AAV) Clade F vectors or AAV vector variants (relative to AAV9) for precise editing of the genome of a cell and methods and kits thereof are provided.
Saswati Chatterjee, Laura Jane Smith, Kamehameha Wong
Filed: 24 Apr 20
Utility
Producing Astrocytes Using Small Molecules
1 Sep 22
Disclosed herein are methods of reprograming autologous tissues or cells into astrocytes or astroglial progenitor cells using one or more small molecule compounds only without any transgenes.
Yanhong SHI, E. TIAN
Filed: 29 Mar 22
Utility
Solution Formulations of CX-011
1 Sep 22
Provided herein are solution formulations of CX-011 and related methods for making solution formulations of CX-011.
Yuelong MA, Rajiv NALLU, David HORNE
Filed: 22 Feb 22
Utility
5-BROMO-INDIRUBINS
1 Sep 22
Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
Richard JOVE, Sangkil NAM, David HORNE, Jun XIE, Alexios Leandros SKALTSOUNIS, Marina KRITSANIDA, Nicolas GABORIAUD-KOLAR
Filed: 9 Mar 22
Utility
Compositions and Methods for the Treatment of Hypercholesterolemia
1 Sep 22
Provided herein are, inter alia, compositions and methods for the treatment of hypercholesterolemia.
Kevin V. MORRIS, Roslyn RAY
Filed: 2 Feb 22
Utility
Coexpression of CAS9 and TREX2 for targeted mutagenesis
30 Aug 22
A composition used in targeted mutagenesis is provided, which includes a first expression cassette comprising a nucleotide sequence which encodes a CAS9 endonuclease; a second expression cassette comprising a nucleotide sequence which encodes a guide RNA sequence, wherein the guide RNA sequence is complementary to a target genome nucleotide sequence in a cell; and a third expression cassette comprising a nucleotide sequence which encodes a Trex2 exonuclease (Trex2) gene.
Jeremy M. Stark, Diana Yanez
Filed: 5 Dec 18
Utility
RNA aptamers against transferrin receptor (TfR)
30 Aug 22
A ribonucleic acid compound is disclosed, the ribonucleic acid compound comprising, or consisting of, an RNA sequence having at least 90% sequence identity to SEQ ID NO: 1, wherein said RNA sequence has a length of 29 nucleotides or fewer, and wherein the RNA sequence is capable of binding to a transferrin receptor (TfR).
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 10 Aug 18
Utility
Methods and Compositions to Direct Breakdown of Insulin Mrna In Benign Fashion
25 Aug 22
Methods and compositions discussed herein allow for preventing or treating type 1 diabetes (T1D) including directing the breakdown of insulin mRNA.
Bart Otto ROEP, Rene Matthijs VAN TIENHOVEN
Filed: 10 Mar 22
Utility
Chimeric Antigen Receptors Targeting HER2
25 Aug 22
Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain targeted to HER2, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.
Saul J. Priceman, Stephen J. Forman, Christine E. Brown
Filed: 6 Dec 21
Utility
Producing astrocytes using small molecules
16 Aug 22
Disclosed herein are methods of reprograming autologous tissues or cells into astrocytes or astroglial progenitor cells using one or more small molecule compounds only without any transgenes.
Yanhong Shi, E. Tian
Filed: 21 Jun 17